The information contained within this announcement is deemed to constitute inside information as stipulated under the retained EU law version of the Market Abuse Regulation (EU) No. 596/2014 (the "UK ...
Preliminary 2024 total revenue of $555 million to $560 million, exceeding top end of guidance, including Crysvita® revenue of $405 million to $410 million, and Dojolvi® revenue of ...
1. AISC is a non-GAAP measure. See the "Non-GAAP Measures" section of this news release for additional information. 2. Exchange rates used to forecast cost metrics include MXN/USD of 19.0 and CAD/USD ...